* Corresponding author: Manisha A. Lavate Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0. Solid lipid nanoparticles; as a promising drug delivery method to get greater bioavailability: A review Manisha A. Lavate * , Sujit T. Karpe, Sidaray N. Biradar and Madanna R. Bhandare Department of Pharmacology, Sojar College of Pharmacy, Khandvi Barshi 411038, Maharashtra, India. World Journal of Biology Pharmacy and Health Sciences, 2023, 14(02), 072–080 Publication history: Received on 16 January 2023; revised on 05 May 2023; accepted on 08 May 2023 Article DOI: https://doi.org/10.30574/wjbphs.2023.14.2.0104 Abstract Solid lipid nanoparticles (SLN) are the heart of nanotechnology's tremendous development, with multiple practical benefits in drug delivery and research. Because of their size-dependent properties, solid Lipid nanoparticles can be used to create innovative medicines. Drug conversion into nanoparticles provides a new drug delivery concept that could be used for drug targeting. As a result, solid lipid nanoparticles have great promise reaching the goal of targeted and site- specific drug delivery. The goals, production techniques, advantages, limits are all discussed in this review. Scanning electron microscopy and measurement of particle size and zeta potential, dynamic light scattering are examples of appropriate analytical techniques for SLN characterization. By using novel drug formulation technologies, the drug delivery system focuses on the regulation of in vivo dynamics in order to enhance the efficacy and safety of the included pharmaceuticals. Lipids used in the development of Nano particulate dosage forms, such as fatty acids, triglycerides, vegetable oils, and their derivatives. Solid lipid nanoparticles (SLNs) are a type of lipid drug delivery method that is relatively new. They were created to solve some of the limitations with traditional drug delivery systems, such as low drug encapsulation efficiency and limited bioavailability of Biopharmaceutical Classification Systems (BCS) class II and IV medications. SLNs are made up of physiologically well tolerated substances and melt-emulsified lipids that are solid at room temperature that helps to enhance drug bioavailability ultimately results in better desired therapeutic effect. Keywords: SLNs; BCS class II; Targeted drug delivery; Zeta potential; Ultra-sonication 1. Introduction Solid lipid nanoparticles (SLNs) are generally known as lipid nanoparticles (LNPs).SLNs are lipid-based nanoparticles. They are an innovative pharmaceutical drug delivery method as well as a new pharmaceutical formulation (1). Solid lipid nanoparticles (SLN) were first introduced in 1991 as an alternative to traditional colloidal carriers like emulsions, liposomes, and polymeric micro and nanoparticles. As an alternate particulate carrier system, nanoparticles produced from solid lipids are getting a lot of attention as a new colloidal drug carrier for intravenous applications. SLNs are sub-micron colloidal carriers with diameters ranging from 50 to 1000 nm, made up of physiological lipid and dispersed in water or an aqueous surfactant solution. SLN are appealing for their potential to increase pharmaceutical efficacy due to their unique qualities such as tiny size, vast surface area, high drug loading, and phase interaction at the interface. Solid lipid nanoparticles are an innovative possible colloidal carrier system as an alternative to polymers that is identical to oil in water emulsion. The liquid lipid has been replaced with a solid lipid.